This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, L. Articles by Pollock, R. E. Search for Related Content PubMed PubMed Citation Articles by Zhang, L. Articles by Pollock, R. E.

Wild-Type p53 Suppresses Angiogenesis in Human Leiomyosarcoma and Synovial Sarcoma by Transcriptional Suppression of Vascular Endothelial Growth Factor Expression¹

Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Our recent studies (R. Pollock et al., Clin. Cancer Res., 4: 1985–1994, 1998; M. Milas et al., Cancer Gene Ther., in press, 2000) have shown that the restoration of wild-type (wt) p53 enhances cell cycle control in vitro and inhibits the growth of human soft-tissue sarcoma in severe combined immunodeficient mice. We hypothesized that the antitumor effect of wt p53 overexpression in sarcoma cells is attributable not only to enhanced cell cycle control but also to inhibition of angiogenesis. We evaluated the effect of restoring wt p53 function on angiogenesis in human soft-tissue sarcoma harboring mutant p53. Restoration of wt p53 expression in human leiomyosarcoma SKLMS-1 cells that contain mutant p53 markedly inhibited angiogenesis induced by tumor cells in vivo. Angiogenesis assays using an in vivo Matrigel plug assay demonstrated that less neovascularization in severe combined immunodeficient mice was observed with conditioned medium (CM) from human synovial sarcoma cells expressing wt p53 compared with CM from human synovial sarcoma cells expressing mutant p53. Microvessel density and microvessel counts were lower in tumor xenografts from cells containing wt p53 than in tumor xenografts from cells containing mutant p53. The growth and migration of murine lung endothelial cells were decreased when cells were treated with CM from sarcoma cells expressing wt p53 compared with CM from sarcoma cells expressing mutant p53. The introduction of wt p53 into sarcoma cells containing mutant p53 significantly reduced the expression of vascular endothelial growth factor (VEGF), which is a key mediator of tumor angiogenesis. Stimulation of endothelial cell migration by CM from cells expressing mutant p53 was significantly reduced after anti-VEGF neutralizing antibody was added to the CM. Using luciferase as the reporter of VEGF promoter activity, we found that wt p53 inhibited VEGF promoter activity in SKLMS-1 cells. Deletion analysis defined an 87-bp region (bp -135 to -48) in the VEGF promoter that is necessary for inhibiting VEGF promoter activity by wt p53. The transcription factor Sp1 may be involved in the repression of VEGF promoter activity by wt p53 in SKLMS-1 cells. These data indicated that wt p53 can suppress angiogenesis in human soft-tissue sarcomas by transcriptional repression of VEGF expression.

This article has been cited by other articles:

				D. BOCANGEL, S. SENGUPTA, S. MITRA, and K. K. BHAKAT p53-Mediated Down-regulation of the Human DNA Repair Gene O6-Methylguanine-DNA Methyltransferase (MGMT) via Interaction with Sp1 Transcription Factor Anticancer Res, October 1, 2009; 29(10): 3741 - 3750. [Abstract] [Full Text] [PDF]

				X. Sun, L. Wei, Q. Chen, and R. M. Terek HDAC4 Represses Vascular Endothelial Growth Factor Expression in Chondrosarcoma by Modulating RUNX2 Activity J. Biol. Chem., August 14, 2009; 284(33): 21881 - 21890. [Abstract] [Full Text] [PDF]

				J.-j. Pan, S.-w. Zhang, C.-b. Chen, S.-w. Xiao, Y. Sun, C.-q. Liu, X. Su, D.-m. Li, G. Xu, B. Xu, et al. Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., February 10, 2009; 27(5): 799 - 804. [Abstract] [Full Text] [PDF]

				D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation Vascular and Endovascular Surgery, January 1, 2009; 42(6): 517 - 530. [Abstract] [PDF]

				H. K. Eltzschig, D. Kohler, T. Eckle, T. Kong, S. C. Robson, and S. P. Colgan Central role of Sp1-regulated CD39 in hypoxia/ischemia protection Blood, January 1, 2009; 113(1): 224 - 232. [Abstract] [Full Text] [PDF]

				L. H. Baker, E. K. Rowinsky, D. Mendelson, R. A. Humerickhouse, R. A. Knight, J. Qian, R. A. Carr, G. B. Gordon, and G. D. Demetri Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma J. Clin. Oncol., December 1, 2008; 26(34): 5583 - 5588. [Abstract] [Full Text] [PDF]

				A. Zaky, C. Busso, T. Izumi, R. Chattopadhyay, A. Bassiouny, S. Mitra, and K. K. Bhakat Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage Nucleic Acids Res., March 1, 2008; 36(5): 1555 - 1566. [Abstract] [Full Text] [PDF]

				J. Harper, L. Yan, R. M. Loureiro, I. Wu, J. Fang, P. A. D'Amore, and M. A. Moses Repression of Vascular Endothelial Growth Factor Expression by the Zinc Finger Transcription Factor ZNF24 Cancer Res., September 15, 2007; 67(18): 8736 - 8741. [Abstract] [Full Text] [PDF]

				J. A.F. Hannay, J. Liu, Q.-S. Zhu, S. V. Bolshakov, L. Li, P. W.T. Pisters, A. J.F. Lazar, D. Yu, R. E. Pollock, and D. Lev Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation Mol. Cancer Ther., May 1, 2007; 6(5): 1650 - 1660. [Abstract] [Full Text] [PDF]

				D. Menendez, A. Inga, J. Snipe, O. Krysiak, G. Schonfelder, and M. A. Resnick A Single-Nucleotide Polymorphism in a Half-Binding Site Creates p53 and Estrogen Receptor Control of Vascular Endothelial Growth Factor Receptor 1 Mol. Cell. Biol., April 1, 2007; 27(7): 2590 - 2600. [Abstract] [Full Text] [PDF]

				J. Liu, M. Zhan, J. A.F. Hannay, P. Das, S. V. Bolshakov, D. Kotilingam, D. Yu, A. F. Lazar, R. E. Pollock, and D. Lev Wild-type p53 Inhibits Nuclear Factor-{kappa}B-Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis Mol. Cancer Res., November 1, 2006; 4(11): 803 - 810. [Abstract] [Full Text] [PDF]

				J. Folkman Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin Sci. Signal., September 26, 2006; 2006(354): pe35 - pe35. [Abstract] [Full Text] [PDF]

				L. Zhang, J. A.F. Hannay, J. Liu, P. Das, M. Zhan, T. Nguyen, D. J. Hicklin, D. Yu, R. E. Pollock, and D. Lev Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance. Cancer Res., September 1, 2006; 66(17): 8770 - 8778. [Abstract] [Full Text] [PDF]

				J. G. Teodoro, A. E. Parker, X. Zhu, and M. R. Green p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science, August 18, 2006; 313(5789): 968 - 971. [Abstract] [Full Text] [PDF]

				G. Qin, R. Kishore, C. M. Dolan, M. Silver, A. Wecker, C. N. Luedemann, T. Thorne, A. Hanley, C. Curry, L. Heyd, et al. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF PNAS, July 18, 2006; 103(29): 11015 - 11020. [Abstract] [Full Text] [PDF]

				A. J. Garton, A. P.A. Crew, M. Franklin, A. R. Cooke, G. M. Wynne, L. Castaldo, J. Kahler, S. L. Winski, A. Franks, E. N. Brown, et al. OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models Cancer Res., January 15, 2006; 66(2): 1015 - 1024. [Abstract] [Full Text] [PDF]

				C. Miled, M. Pontoglio, S. Garbay, M. Yaniv, and J. B. Weitzman A Genomic Map of p53 Binding Sites Identifies Novel p53 Targets Involved in an Apoptotic Network Cancer Res., June 15, 2005; 65(12): 5096 - 5104. [Abstract] [Full Text] [PDF]

				M.-K. Bae, J.-W. Jeong, S.-H. Kim, S.-Y. Kim, H. J. Kang, D.-M. Kim, S.-K. Bae, I. Yun, G. A. Trentin, M. Rozakis-Adcock, et al. Tid-1 Interacts with the von Hippel-Lindau Protein and Modulates Angiogenesis by Destabilization of HIF-1{alpha} Cancer Res., April 1, 2005; 65(7): 2520 - 2525. [Abstract] [Full Text] [PDF]

				G. Pages and J. Pouyssegur Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors Cardiovasc Res, February 15, 2005; 65(3): 564 - 573. [Abstract] [Full Text] [PDF]

				M. Zhan, D. Yu, J. Liu, J. Hannay, and R. E. Pollock Transcriptional Repression of Protein Kinase C{alpha} via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation J. Biol. Chem., February 11, 2005; 280(6): 4825 - 4833. [Abstract] [Full Text] [PDF]

				J. Wu, S. Brandt, and S. M. Hyder Ligand- and Cell-Specific Effects of Signal Transduction Pathway Inhibitors on Progestin-Induced Vascular Endothelial Growth Factor Levels in Human Breast Cancer Cells Mol. Endocrinol., February 1, 2005; 19(2): 312 - 326. [Abstract] [Full Text] [PDF]

				D. W. Siemann, M. C. Bibby, G. G. Dark, A. P. Dicker, F. A.L.M. Eskens, M. R. Horsman, D. Marme, and P. M. LoRusso Differentiation and Definition of Vascular-Targeted Therapies Clin. Cancer Res., January 15, 2005; 11(2): 416 - 420. [Abstract] [Full Text] [PDF]

				J. FOLKMAN and S. RYEOM Is Oncogene Addiction Angiogenesis-dependent? Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 389 - 397. [Abstract] [PDF]

				K. Nakamura, A. Yamamoto, M. Kamishohara, K. Takahashi, E. Taguchi, T. Miura, K. Kubo, M. Shibuya, and T. Isoe KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth Mol. Cancer Ther., December 1, 2004; 3(12): 1639 - 1649. [Abstract] [Full Text] [PDF]

				H. Hallaq, E. Pinter, J. Enciso, J. McGrath, C. Zeiss, M. Brueckner, J. Madri, H. C. Jacobs, C. M. Wilson, H. Vasavada, et al. A null mutation of Hhex results in abnormal cardiac development, defective vasculogenesis and elevated Vegfa levels Development, October 15, 2004; 131(20): 5197 - 5209. [Abstract] [Full Text] [PDF]

				M. Kaluzova, S. Kaluz, M. I. Lerman, and E. J. Stanbridge DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1{alpha} in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX Mol. Cell. Biol., July 1, 2004; 24(13): 5757 - 5766. [Abstract] [Full Text] [PDF]

				D. Wei, L. Wang, Y. He, H. Q. Xiong, J. L. Abbruzzese, and K. Xie Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity Cancer Res., March 15, 2004; 64(6): 2030 - 2038. [Abstract] [Full Text] [PDF]

				M. Ruiz, C. Pettaway, R. Song, O. Stoeltzing, L. Ellis, and M. Bar-Eli Activator Protein 2{alpha} Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer Cells Cancer Res., January 15, 2004; 64(2): 631 - 638. [Abstract] [Full Text] [PDF]

				H. Schwarzenbach, G. Chakrabarti, H. J. Paust, and A. K. Mukhopadhyay Gonadotropin-Mediated Regulation of the Murine VEGF Expression in MA-10 Leydig Cells J Androl, January 1, 2004; 25(1): 128 - 139. [Abstract] [Full Text] [PDF]

				H.-T. Yuan, X.-Z. Li, J. E. Pitera, D. A. Long, and A. S. Woolf Peritubular Capillary Loss after Mouse Acute Nephrotoxicity Correlates with Down-Regulation of Vascular Endothelial Growth Factor-A and Hypoxia-Inducible Factor-1{alpha} Am. J. Pathol., December 1, 2003; 163(6): 2289 - 2301. [Abstract] [Full Text]

				N Raghunand, R A Gatenby, and R J Gillies Microenvironmental and cellular consequences of altered blood flow in tumours Br. J. Radiol., December 1, 2003; 76(suppl_1): S11 - S22. [Abstract] [Full Text] [PDF]

				L. P. Lefter, M. Sunamura, T. Furukawa, K. Takeda, N. Kotobuki, M. Oshimura, S. Matsuno, and A. Horii Inserting Chromosome 18 into Pancreatic Cancer Cells Switches Them to a Dormant Metastatic Phenotype Clin. Cancer Res., October 15, 2003; 9(13): 5044 - 5052. [Abstract] [Full Text] [PDF]

				H. Zheng, C. Wasylyk, A. Ayadi, J. Abecassis, J. A Schalken, H. Rogatsch, N. Wernert, S.-M. Maira, M.-C. Multon, and B. Wasylyk The transcription factor Net regulates the angiogenic switch Genes & Dev., September 15, 2003; 17(18): 2283 - 2297. [Abstract] [Full Text] [PDF]

				O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma Am. J. Pathol., August 1, 2003; 163(2): 723 - 732. [Abstract] [Full Text] [PDF]

				T. Abe, K. Terada, H. Wakimoto, R. Inoue, E. Tyminski, R. Bookstein, J. P. Basilion, and E. A. Chiocca PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli Cancer Res., May 1, 2003; 63(9): 2300 - 2305. [Abstract] [Full Text] [PDF]

				W. A. Weiss, M. J. Burns, C. Hackett, K. Aldape, J. R. Hill, H. Kuriyama, N. Kuriyama, N. Milshteyn, T. Roberts, M. F. Wendland, et al. Genetic Determinants of Malignancy in a Mouse Model for Oligodendroglioma Cancer Res., April 1, 2003; 63(7): 1589 - 1595. [Abstract] [Full Text] [PDF]

				K. Reisinger, R. Kaufmann, and J. Gille Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription J. Cell Sci., January 15, 2003; 116(2): 225 - 238. [Abstract] [Full Text] [PDF]

				H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF]

				E.-J. Kim, J.-S. Park, and S.-J. Um Identification and Characterization of HIPK2 Interacting with p73 and Modulating Functions of the p53 Family in Vivo J. Biol. Chem., August 23, 2002; 277(35): 32020 - 32028. [Abstract] [Full Text] [PDF]

				S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J. A. Jackson, S. J. Boffey, P. J. Valentine, J. O. Curwen, H. L. Musgrove, et al. ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration Cancer Res., August 15, 2002; 62(16): 4645 - 4655. [Abstract] [Full Text] [PDF]

				E. M. Hammond, A. J. Giaccia, T. Browder, J. Folkman, P. Hahnfeldt, J. Heymach, L. Hlatky, M. Kieran, M. S. Rogers, Robert. S. Kerbel, et al. Antiangiogenic Therapy and p53 Science, July 26, 2002; 297(5581): 471a - 471. [Abstract] [Full Text] [PDF]

				J. Milanini-Mongiat, J. Pouyssegur, and G. Pages Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases. THEIR IMPLICATION IN VASCULAR ENDOTHELIAL GROWTH FACTOR GENE TRANSCRIPTION J. Biol. Chem., May 31, 2002; 277(23): 20631 - 20639. [Abstract] [Full Text] [PDF]

				L. Zhang, D. Yu, D. J. Hicklin, J. A. F. Hannay, L. M. Ellis, and R. E. Pollock Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Growth of Human Soft Tissue Sarcoma Xenografts by Induction of Endothelial Cell Apoptosis Cancer Res., April 1, 2002; 62(7): 2034 - 2042. [Abstract] [Full Text] [PDF]

				R. N. McKeller, J. L. Fowler, J. J. Cunningham, N. Warner, R. J. Smeyne, F. Zindy, and S. X. Skapek The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development PNAS, March 19, 2002; 99(6): 3848 - 3853. [Abstract] [Full Text] [PDF]

				Y.-T. Tai, K. Podar, D. Gupta, B. Lin, G. Young, M. Akiyama, and K. C. Anderson CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells Blood, February 15, 2002; 99(4): 1419 - 1427. [Abstract] [Full Text] [PDF]

				C. Pollmann, X. Huang, J. Mall, D. Bech-Otschir, M. Naumann, and W. Dubiel The Constitutive Photomorphogenesis 9 Signalosome Directs Vascular Endothelial Growth Factor Production in Tumor Cells Cancer Res., December 1, 2001; 61(23): 8416 - 8421. [Abstract] [Full Text] [PDF]

				X. Lu, G. Magrane, C. Yin, D. N. Louis, J. Gray, and T. Van Dyke Selective Inactivation of p53 Facilitates Mouse Epithelial Tumor Progression without Chromosomal Instability Mol. Cell. Biol., September 1, 2001; 21(17): 6017 - 6030. [Abstract] [Full Text] [PDF]

				K. S. Srivenugopal, J. Shou, S. R. S. Mullapudi, F. F. Lang Jr., J. S. Rao, and F. Ali-Osman Enforced Expression of Wild-Type p53 Curtails the Transcription of the O6-Methylguanine-DNA Methyltransferase Gene in Human Tumor Cells and Enhances Their Sensitivity to Alkylating Agents Clin. Cancer Res., May 1, 2001; 7(5): 1398 - 1409. [Abstract] [Full Text]

				S. Xiong, R. Grijalva, L. Zhang, N. T. Nguyen, P. W. Pisters, R. E. Pollock, and D. Yu Up-Regulation of Vascular Endothelial Growth Factor in Breast Cancer Cells by the Heregulin-{beta}1-activated p38 Signaling Pathway Enhances Endothelial Cell Migration Cancer Res., February 1, 2001; 61(4): 1727 - 1732. [Abstract] [Full Text]

				B. Li and M. Y. W. Lee Transcriptional Regulation of the Human DNA Polymerase delta Catalytic Subunit Gene POLD1 by p53 Tumor Suppressor and Sp1 J. Biol. Chem., August 3, 2001; 276(32): 29729 - 29739. [Abstract] [Full Text] [PDF]

				G. Koutsodontis, I. Tentes, P. Papakosta, A. Moustakas, and D. Kardassis Sp1 Plays a Critical Role in the Transcriptional Activation of the Human Cyclin-dependent Kinase Inhibitor p21WAF1/Cip1 Gene by the p53 Tumor Suppressor Protein J. Biol. Chem., July 27, 2001; 276(31): 29116 - 29125. [Abstract] [Full Text] [PDF]